Notably,ATRX mutations are frequently observed in female gastric cancer patients with high microsatellite instability (MSI), tumor mutational burden (TMB), and programmed death-ligand 1 (PD-L1) expression; these characteristics are purported to be predictive biomarkers for immunotherapy response (Ge et al. 2021). Here, ATRX is linked to neoplasm.